Supreme Court will rule on patent licensing dispute

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Supreme Court will rule on patent licensing dispute

The US Supreme Court agreed on Monday to accept a patent dispute between Boston Scientific and medical devices manufacturer Medtronic

The case, Medtronic v Boston Scientific, concerns patents relating to a device made by Medtronic known as cardiac resynchronization therapy (CRT). The equipment tracks the patient’s heartbeat to ensure both the right and left ventricles contract simultaneously, and administers electric shocks to restore the proper balance if they get out of sync.

The patents are owned by Mirowski Family Ventures, which licensed them exclusively to Natick, Massachusetts-based Boston Scientific.

The companies agreed that Medtronic would license the patents and pay royalties if it produced any new products which used the technology covered by them.

In 2007, Mirowski alleged that new products Medtronic was developing qualified for royalty fees.

Medtronic subsequently sued, seeking a declaratory judgment that it had not infringed the patents, US reissue patents RE38,119 and RE39,897. Medtronic claims that the onus falls on the patent owner to prove infringement.

A Delaware court ruled that Medtronic was not infringing, but the Federal Circuit overturned the decision in September 2012, concluding that the onus was on Medtronic to prove that it hadn’t infringed.

Usually, the burden of proving infringement falls to the patent holder. But the Federal Circuit reversed this approach, deciding instead to shift the burden to Medtronic because the Fridley-based company was a licensee seeking a declaratory judgment of non-infringement.

The Supreme Court will now review whether the Federal Circuit’s decision to shift the burden was correct. Medtronic claims the appellate court’s ruling creates a loophole allowing patent owners a risk-free way to increase the scope of their licenses to cover new products.

Medtronic has so far been represented by Robins Kaplan Miller & Ciresi in the case and Mirowski has been represented by Oblon Spivak McClelland Maier & Neustadt.

more from across site and SHARED ros bottom lb

More from across our site

The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
The firm said major IP developments included advising on a ‘landmark’ deal involving green hydrogen production, as well as two major acquisitions
The appointments follow other recent moves in the European market as firms look to bolster their UPC offerings
Deborah Kirk discusses why IP and technology have become central pillars in transactions and explains why clients need practically minded lawyers
Gift this article